This webinar will discuss the FDA's current thinking on good practices
for disseminating off-label information by firms for their FDA-approved
or cleared products (drugs for both human and animals and medical
devices for humans). This webinar will also discuss the FDA proposed
and recommended practices for responding to both non-public and
public unsolicited requests made through emerging electronic media
(e.g., social media or other public electronic media). In addition,
several public comments will be discussed in response to the FDA's
recent guidance document.